Latest filing published 29 Sept 2026 for Kura Oncology, Inc., €78k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Teresa Brophy Bair in Kura Oncology, Inc. In total, 19 filings cover trades dated from 17 November 2022 to 28 September 2026.
The open-market record consists of 13 sales worth €834k, with no purchase. Other entries cover 6 share grants. So far in 2026, the count stands at no purchases and 5 sales.
Most recently, on 29 September 2026, the filings show an open-market sale worth €78k in Kura Oncology, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations